What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of. Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 326 since coronavirus was declared a global pandemic.

Today's main story, Biden's new COVID-Zar is known among Democrats as a problem solver.

But will that be enough for the job ahead?

But first, here's what happened in virus news today.

Astrozenica and the University of Oxford are planning to have a re-engineered shot that protects against new mutations available by the fall.

The more protective vaccine would come just in time for another round of immunizations that may be required before next winter.

Andrew Pollard, chief investigator of the Oxford trials,

said switching out the genome sequence,

manufacturing and completing new studies for a vaccine against variants

should be fairly quick.

A new study shows promising signs

for the immunity of people who have been infected with COVID-19.

According to a report by UK Biobank, a major biomedical database,

some 88% of participants who tested positive for a previous infection retained antibodies for six months.

At three months, the number was 99%. The results follow other smaller studies

that indicate some level of immunity

for at least six months after a natural infection.

Finally, Mexico's health agency approved Russia's Sputnik 5 vaccine for emergency use.

...